BDR Pharmaceutical launches generic drug for treating prostate cancer in India

BDR Group Director Business Development Raheel Shah said that the launch of APATIDE is “testimony towards our commitment in providing access to affordable medicines without compromising patients’ safety as well as qualitative standards”.